<SEC-DOCUMENT>0001078782-17-001347.txt : 20171004
<SEC-HEADER>0001078782-17-001347.hdr.sgml : 20171004
<ACCEPTANCE-DATETIME>20171004170438
ACCESSION NUMBER:		0001078782-17-001347
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20171004
DATE AS OF CHANGE:		20171004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SIGMA LABS, INC.
		CENTRAL INDEX KEY:			0000788611
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS MANUFACTURING INDUSTRIES [3990]
		IRS NUMBER:				820404220
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-218021
		FILM NUMBER:		171122357

	BUSINESS ADDRESS:	
		STREET 1:		3900 PASEO DEL SOL
		CITY:			SANTE FE
		STATE:			NM
		ZIP:			87507
		BUSINESS PHONE:		(505) 438-2576

	MAIL ADDRESS:	
		STREET 1:		3900 PASEO DEL SOL
		CITY:			SANTE FE
		STATE:			NM
		ZIP:			87507

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FRAMEWAVES INC
		DATE OF NAME CHANGE:	20010130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MESSIDOR LTD
		DATE OF NAME CHANGE:	20010122
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>424b3100417_424b3.htm
<DESCRIPTION>424B3 PROSPECTUS SUPPLEMENT NO. 2
<TEXT>
<HTML>
<!-- Produced by Justeene Blankenship using EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2017 [PPXAC8S3T1P2VKXCJE4E]. www.edgarsuite.com -->
<HEAD>
<TITLE>424b3 Prospectus Supplement No. 2</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:36pt;width:540pt><P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:275.4pt><P align=justify style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>PROSPECTUS SUPPLEMENT NO. 2</B></FONT></P>
</TD><TD valign=top style=width:275.4pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;<FONT style=font-size:10pt><B>Filed Pursuant to Rule 424(b)(3) </B></FONT></P>
</TD></TR>
<TR><TD valign=top style=width:275.4pt><P align=justify style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>(to Prospectus Supplement No. 1 dated</B></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>September 19, 2017 and the Prospectus dated May 18, 2017)</B></FONT></P>
</TD><TD valign=top style=width:275.4pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;<FONT style=font-size:10pt><B>Registration No. 333-218021</B></FONT></P>
</TD></TR>
</TABLE>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>434,877 Shares of Common Stock</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><IMG src=f424b3100417_424b31.jpg width=226 height=65 alt='Picture 1' title='Picture 1'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'><FONT style=font-size:10pt>This Prospectus Supplement No. 2 (this &#8220;Supplement No. 2&#8221;) supplements the information contained in our Prospectus Supplement No. 1 dated September 19, 2017 (&quot;Supplement No. 1&quot;) and our Prospectus dated May 18, 2017 (the &#8220;Prospectus&#8221;). Supplement No. 1 and the Prospectus form a part of our Registration Statement on Form S-1, Registration No. 333-218021, which we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on May 15, 2017.</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'><FONT style=font-size:10pt>The Prospectus relates to the offer and sale from time to time of up to 434,877 shares of our common stock by two of our stockholders, referred to in the Prospectus as the &#8220;selling stockholders.&#8221; </FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'><FONT style=font-size:10pt>The purpose of this Supplement No. 2 is to disclose that we have agreed with each selling stockholder (1) to reduce the exercise price of its common stock purchase warrants from $4.13 per share to $2.00 per share and (2) to reduce the conversion price of its 10% secured convertible note from $4.13 per share to $2.00 per share. In consideration of the foregoing, each selling stockholder has agreed, among other things, to extend the payment date of 50% of the outstanding principal balance of its secured convertible note from October 17, 2017 to the earlier of May 18, 2018 or the closing of our next underwritten public offering of securities (should we elect to commence and close such an offering of securities). </FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'><FONT style=font-size:10pt>Supplement No. 1 and the Prospectus are amended to the extent described in the preceding paragraph.</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'><FONT style=font-size:10pt>This Supplement No. 2 should be read in conjunction with Supplement No. 1 and the Prospectus and is qualified by reference to Supplement No. 1 and the Prospectus. This Supplement No. 2 is not complete without, and may only be delivered or used in conjunction with, the Prospectus, Supplement No. 1 and any future amendments or supplements thereto.</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'><FONT style=font-size:10pt>This Supplement No. 2 forms a part of Supplement No. 1 and the Prospectus. Except as specifically amended by this Supplement No. 2, all portions of Supplement No. 1 and the Prospectus remain in full force and effect. If there is any inconsistency between the information in the Prospectus, Supplement No. 1 and this Supplement No. 2, you should rely on the information in this Supplement No. 2.</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'><FONT style=font-size:10pt>Our common stock is traded on The NASDAQ Capital Market under the symbol &#8220;SGLB.&#8221; On September 29, 2017, the last reported sale price of our common stock as reported on The NASDAQ Capital Market was $1.88.</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'><FONT style=font-size:10pt><B>Investing in our securities involves a high degree of risk. Please read the &#8220;Risk Factors&#8221; beginning on page 6 of the Prospectus.</B></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'><FONT style=font-size:10pt><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Supplement No. 2, Supplement No. 1 or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><FONT style=font-size:10pt><B>The date of this Prospectus Supplement No. 2 is October 4, 2017.</B></FONT></P>
<HR style='border:0;height:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>f424b3100417_424b31.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 f424b3100417_424b31.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N 8$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
